newsfilter
← Latest News
GlobeNewswire·

INVO Fertility Announces Fiscal Year 2025 Financial Results

  • INVO Fertility reported FY2025 total revenue of $6,841,250, a 5% increase from $6,532,000 in FY2024.
  • Consolidated clinic revenue rose 4% to $6,721,057, while revenue from all clinics including equity method investments reached $8,021,929, up 4%.
  • The company recorded a net loss from continuing operations of $5.3 million, an improvement from the $7.7 million loss in the prior year.
  • Adjusted EBITDA for FY2025 was $(3.2) million, compared to $(2.2) million in FY2024.
  • Financing transactions in late 2025 & early 2026 generated $11.5 million in aggregate gross proceeds to support growth & liability reduction.
  • As of March 31, 2026, all Series C-2 Preferred Stock was converted or retired, warrant liabilities were eliminated, & total common shares outstanding reached approximately 1.8 million by June 2, 2026.
  • The company acquired Indiana-based Family Beginnings in February 2026, expanding its US clinic network to four operational locations & adding $1.2 million in revenue.
  • Wisconsin Fertility Institute joined the Progyny network to broaden employer-sponsored patient access, & the clinic now offers time-lapse incubation technology.
  • A new patent for the modified INVOcell device was issued, extending intellectual property protection through 2040.
  • Organic growth initiatives were launched at the Atlanta clinic in March 2026, & the operations team was strengthened with key clinical support personnel.
  • Management stated the balance sheet is the strongest it has been in over three years, positioning the company to pursue acquisitions & invest in organic growth.